[1] WAKERLEY B R, UNCINI A, YUKI N, et al. Guillain-Barre and Miller Fisher syndromes-new diagnostic classification [J]. Nat Rev Neurol, 2014, 10(9): 537-544.
[2] SHAHRIZAILA N, LEHMANN H C, KUWABARA S. Guil-lain-Barre syndrome [J]. Lancet, 2021, 397(10280): 1214-1228.[3] 朱莹, 周夏俊, 管阳太. Miller-Fisher综合征与Guillain-Barré综合征非核心临床表现、电生理及脑脊液比较[J]. 中国神经免疫学和神经病学杂志, 2018, 25(1):22-25, 31.
[4] YUKI N, HARTUNG H P. Guillain-Barre syndrome [J]. N Engl J Med, 2012, 366(24): 2294-2304.
[5] 邢燕蒙, 刘沛东, 张保朝, 等. Miller-Fisher综合征临床特点及亚型诊断(附27例报告)[J]. 中国神经免疫学和神经病学杂志, 2016, 23(3):203-206.
[6] MORI M, KUWABARA S, FUKUTAKE T, et al. Intravenous immunoglobulin therapy for Miller Fisher syndrome [J]. Neurology, 2007, 68(14): 1144-1146.
[7] 徐晓涵. 氟喹诺酮类药物存在致残和永久严重不良反应风险[J]. 中国食品药品监管, 2017(3):77.
[8] MORALES D, PACURARIU A, SLATTERY J, et al. Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy[J]. JAMA Neurol, 2019, 76(7):827-833.
[9] 范鸣. 氟喹诺酮类抗生素可诱发严重性外周神经病变[J]. 药学进展, 2013, 37(8):417.
[10] 孙忠实.再议氟喹诺酮类抗菌药物的安全性[J]. 中国医院用药评价与分析, 2013, 13(12):1057-1059.
[11] 熊勋波,向明清,成祥林.莫西沙星致痛性周围神经病1例[J]. 中国民康医学, 2015, 27(10):130. |
